

**H. S. Yathirajan,<sup>a</sup> B. Narayana,<sup>b</sup>  
B. Ashalatha,<sup>b</sup> B. K. Sarojini<sup>c</sup> and  
Michael Bolte<sup>d\*</sup>**

<sup>a</sup>Department of Studies in Chemistry, University of Mysore, Manasagangotri, Mysore 570 006, India, <sup>b</sup>Department of Chemistry, Mangalore University, Mangalagangotri 574 199, India, <sup>c</sup>Department of Chemistry, P. A. College of Engineering, Nadupadavu, Mangalore 574 153, India, and <sup>d</sup>Institut für Anorganische Chemie, J. W. Goethe-Universität Frankfurt, Max-von-Laue-Strasse 7, 60438 Frankfurt/Main, Germany

Correspondence e-mail:  
bolte@chemie.uni-frankfurt.de

**Key indicators**

Single-crystal X-ray study  
 $T = 173$  K  
Mean  $\sigma(\text{C}-\text{C}) = 0.002$  Å  
 $R$  factor = 0.037  
 $wR$  factor = 0.102  
Data-to-parameter ratio = 13.8

For details of how these key indicators were automatically derived from the article, see <http://journals.iucr.org/e>.


**3-(6-Methoxy-2-naphthyl)-1-(2-thienyl)-prop-2-en-1-one**

The molecule of the title compound,  $\text{C}_{18}\text{H}_{14}\text{O}_2\text{S}$ , is essentially planar. The central  $\text{C}=\text{C}$  double bond is *trans*-configured. Geometric parameters are in normal ranges.

Received 28 August 2006  
Accepted 4 September 2006

**Comment**

The title compound, (I), is a biologically active compound. Chalcones and their heterocyclic analogues show various biological effects, *e.g.* anti-inflammatory, antitumour, antibacterial, antitubercular, antiviral, antiprotozoal, gastro-protective *etc.* (Opletalova & Sedivy, 1999). The cytotoxic, anticancer, antiviral, antiprotozoal and insecticidal activities of a variety of chalcones have been reviewed, as well as the enzyme-inhibitory properties and miscellaneous activities of some of these molecules (Dimmock *et al.*, 1999). In addition, with appropriate substituents, chalcones are a class of nonlinear optical (NLO) materials (Fichou *et al.*, 1988; Goto *et al.*, 1991; Butcher *et al.*, 2006; Harrison *et al.*, 2006). The crystal structures of 3-hydroxy-1,3-bis(2-thienyl)prop-2-en-1-one (Baxter *et al.*, 1990), 1,3-bis(4-chlorophenyl)prop-2-en-1-one (Wang *et al.*, 2005), 1-(4-bromophenyl)-3-(2-thienyl)prop-2-en-1-one (Patil *et al.*, 2006) and 1-(4-chlorophenyl)-3-(2-thienyl)prop-2-en-1-one (Ng *et al.*, 2006) have been reported. In continuation of our work on the crystal structures of chalcones (Yathirajan, Sarojini, Narayana, Ashalatha & Bolte, 2006; Yathirajan, Sarojini, Bindya, Narayana & Bolte, 2006; Yathirajan, Sarojini, Narayana, Bindya & Bolte, 2006), and in view of their importance, we present here the crystal structure of compound (I).



A perspective view of compound (I) is shown in Fig. 1. Bond lengths and angles can be regarded as normal (Cambridge Structural Database, Version 5.27, November 2005, updated August 2006; *MOGUL*, Version 1.1; Allen, 2002). The aliphatic double bond is *trans* configured. The molecule is essentially planar (r.m.s. deviation for all non-H atoms is 0.056 Å).

**Experimental**

Compound (I) was synthesized according to the method reported in the literature (Vogel, 1989) in a yield of 85%. The compound was

purified by recrystallization from ethanol. Crystal growth was carried out in an acetone–toluene (50:50 v/v) solvent mixture by the slow evaporation technique (m.p. 418–420 K). Analysis for C<sub>18</sub>H<sub>14</sub>O<sub>2</sub>S, found (calculated): C 73.40 (73.44), H 4.75 (4.79)%.

### Crystal data

C<sub>18</sub>H<sub>14</sub>O<sub>2</sub>S  
*M<sub>r</sub>* = 294.35  
 Monoclinic, *P*2<sub>1</sub>/*c*  
*a* = 3.9155 (3) Å  
*b* = 10.6776 (8) Å  
*c* = 33.521 (3) Å  
 $\beta$  = 93.164 (7)°  
*V* = 1399.3 (2) Å<sup>3</sup>

*Z* = 4  
*D<sub>x</sub>* = 1.397 Mg m<sup>-3</sup>  
 Mo *K*α radiation  
 $\mu$  = 0.23 mm<sup>-1</sup>  
*T* = 173 (2) K  
 Rod, yellow  
 0.22 × 0.12 × 0.12 mm

### Data collection

Stoe IPDS II two-circle diffractometer  
 $\omega$  scans  
 Absorption correction: multi-scan (*MULABS*; Spek, 2003; Blessing, 1995)  
*T<sub>min</sub>* = 0.951, *T<sub>max</sub>* = 0.970

10698 measured reflections  
 2641 independent reflections  
 2315 reflections with *I* > 2σ(*I*)  
*R<sub>int</sub>* = 0.043  
 $\theta_{\text{max}}$  = 25.7°

### Refinement


Refinement on *F*<sup>2</sup>  
*R* [*F*<sup>2</sup> > 2σ(*F*<sup>2</sup>)] = 0.037  
*wR* (*F*<sup>2</sup>) = 0.102  
*S* = 1.05  
 2641 reflections  
 192 parameters  
 H-atom parameters constrained

$w = 1/[\sigma^2(F_o^2) + (0.0685P)^2 + 0.1527P]$   
 where  $P = (F_o^2 + 2F_c^2)/3$   
 $(\Delta/\sigma)_{\text{max}} = 0.001$   
 $\Delta\rho_{\text{max}} = 0.28 \text{ e } \text{Å}^{-3}$   
 $\Delta\rho_{\text{min}} = -0.34 \text{ e } \text{Å}^{-3}$   
 Extinction correction: *SHELXL97* (Sheldrick, 1997)  
 Extinction coefficient: 0.036 (5)

H atoms were found in a difference map but they were subsequently refined using a riding model, with C–H = 0.95 Å and *U<sub>iso</sub>*(H) = 1.2*U<sub>eq</sub>*(C), or C–H = 0.98 Å and *U<sub>iso</sub>*(H) = 1.5*U<sub>eq</sub>*(C<sub>methyl</sub>). The methyl group was allowed to rotate but not to tip.

Data collection: *X-AREA* (Stoe & Cie, 2001); cell refinement: *X-AREA*; data reduction: *X-AREA*; program(s) used to solve structure: *SHELXS97* (Sheldrick, 1990); program(s) used to refine structure: *SHELXL97* (Sheldrick, 1997); molecular graphics: *PLATON* (Spek, 2003); software used to prepare material for publication: *SHELXL97*.

BKS thanks the AICTE, Government of India, for financial assistance through the Career Award for Young Teachers Scheme.



**Figure 1**

The molecular structure of the title compound, with the atom numbering; displacement ellipsoids are drawn at the 50% probability level.

### References

- Allen, F. H. (2002). *Acta Cryst.* **B58**, 380–388.  
 Baxter, L. A. M., Blake, A. J., Heath, G. A. & Stephenson, T. A. (1990). *Acta Cryst.* **C46**, 508–510.  
 Blessing, R. H. (1995). *Acta Cryst.* **A51**, 33–38.  
 Butcher, R. J., Yathirajan, H. S., Anilkumar, H. G., Sarojini, B. K. & Narayana, B. (2006). *Acta Cryst.* **E62**, o1659–o1661.  
 Dimmock, J. R., Elias, D. W., Beazely, M. A. & Kandepu, N. M. (1999). *Curr. Med. Chem.* **6**, 1125–1149.  
 Fichou, D., Watanabe, T., Takeda, T., Miyata, S., Goto, Y. & Nakayama, M. (1988). *Jpn. J. Appl. Phys.* **27**, L429–L430.  
 Goto, Y., Hayashi, A., Kimura, Y. & Nakayama, M. (1991). *J. Cryst. Growth*, **108**, 688–698.  
 Harrison, W. T. A., Yathirajan, H. S., Sarojini, B. K., Narayana, B. & Indira, J. (2006). *Acta Cryst.* **E62**, o1647–o1649.  
 Ng, S.-L., Patil, P. S., Razak, I. A., Fun, H.-K. & Dharmaparakash, S. M. (2006). *Acta Cryst.* **E62**, o3200–o3202.  
 Opletalova, V. & Sedivy, D. (1999). *Ceska Slov. Farm.* **48**, 252–255.  
 Patil, P. S., Ng, S.-L., Razak, I. A., Fun, H.-K. & Dharmaparakash, S. M. (2006). *Acta Cryst.* **E62**, o3718–o3720.  
 Sheldrick, G. M. (1990). *Acta Cryst.* **A46**, 467–473.  
 Sheldrick, G. M. (1997). *SHELXL97*. University of Göttingen, Germany.  
 Spek, A. L. (2003). *J. Appl. Cryst.* **36**, 7–13.  
 Stoe & Cie (2001). *X-AREA*. Stoe & Cie, Darmstadt, Germany.  
 Vogel (1989). *Vogel's Text book of Practical Organic Chemistry*, edited by B. S. Furniss, A. J. Hannaford, P. W. G. Smith & A. R. Tatchell, 5th edition, p. 1034. London: Longman Group UK Ltd.  
 Wang, L., Yang, W. & Zhang, D.-C. (2005). *Acta Cryst.* **E61**, o2820–o2822.  
 Yathirajan, H. S., Sarojini, B. K., Bindya, S., Narayana, B. & Bolte, M. (2006). *Acta Cryst.* **E62**, o4046–o4047.  
 Yathirajan, H. S., Sarojini, B. K., Narayana, B., Ashalatha, B. V. & Bolte, M. (2006). *Acta Cryst.* **E62**, o3964–o3965.  
 Yathirajan, H. S., Sarojini, B. K., Narayana, B., Bindya, S. & Bolte, M. (2006). *Acta Cryst.* **E62**, o4048–o4049.